

Claims

This listing of claims will replace all prior versions, and listings, of claims in the application. No amendments are entered or requested at this time.

Listing of Claims:

1. (Original) A method of treating a human or animal having undesirable endothelial cell proliferation comprising,
administering to the human or animal a sufficient amount of a composition comprising a tissue factor pathway inhibitor C-terminal peptide to inhibit the undesirable endothelial cell proliferation.
2. (Original) The method of Claim 1 wherein the undesirable endothelial cell proliferation is an angiogenesis-related disease.
3. (Original) The method of Claim 2, wherein the angiogenesis-related disease is a disease selected from the group consisting of hemangioma, solid tumors, leukemia, metastasis, telangiectasia psoriasis scleroderma, pyogenic granuloma, myocardial angiogenesis, plaque neovascularization, coronary collaterals, ischemic limb angiogenesis, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasia, arthritis, diabetic neovascularization, macular degeneration, wound healing, peptic ulcer, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation, and placentation.
4. (Original) The method of Claim 1 wherein administration of the composition inhibits angiogenesis.
5. (Original) The method of Claim 1 wherein the tissue factor pathway inhibitor is a protein or peptide having the amino acid sequence set forth in SEQ ID NO: 5, a homolog thereof, or an anti-proliferative fragment thereof.

6. (Original) The method of Claim 5 wherein the anti-proliferative fragment is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3.
7. (Original) The method of Claim 5 wherein the anti-proliferative fragment consists of SEQ ID NO: 3.
8. (Original) The method of Claim 1 wherein the tissue factor pathway inhibitor is a protein or peptide having the amino acid sequence set forth in SEQ ID NO. 6, a homolog thereof, or an anti-proliferative fragment thereof.
9. (Original) The method of Claim 8 wherein the anti-proliferative fragment consists of SEQ ID NO: 4.
10. (Original) The method of Claim 1 wherein the composition further comprises a pharmaceutically acceptable excipient, carrier or sustained-release matrix.
11. (Original) A method for treating an angiogenesis-related disease comprising,
administering to a human or animal a sufficient amount of a composition comprising a tissue factor pathway inhibitor C-terminal peptide to inhibit the undesirable endothelial cell proliferation.
12. (Original) The method of Claim 11, wherein the angiogenesis-related disease is a disease selected from the group consisting of hemangioma, solid tumors, leukemia, metastasis, telangiectasia psoriasis scleroderma, pyogenic granuloma, myocardial angiogenesis, plaque neovascularization, coronary collaterals, ischemic limb angiogenesis, corneal diseases, rubeosis, neovascular glaucoma, diabetic retinopathy, retrolental fibroplasia, arthritis, diabetic neovascularization, macular degeneration, wound healing, peptic ulcer, fractures, keloids, vasculogenesis, hematopoiesis, ovulation, menstruation, and placentation.

13. (Original) The method of Claim 11 wherein the tissue factor pathway inhibitor is a protein or peptide having the amino acid sequence set forth in SEQ ID NO. 5, a homolog thereof, or an anti-proliferative fragment thereof.

14. (Original) The method of Claim 13 wherein the anti-proliferative fragment is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3.

15. (Original) The method of Claim 14 wherein the anti-proliferative fragment consists of SEQ ID NO: 3.

16. (Original) The method of Claim 11 wherein the tissue factor pathway inhibitor is a protein or peptide having the amino acid sequence set forth in SEQ ID NO. 6, a homolog thereof, or an anti-proliferative fragment thereof.

17. (Original) The method of Claim 16 wherein the anti-proliferative fragment consists of SEQ ID NO: 4.

18. (Original) The method of Claim 11 wherein the composition further comprises a pharmaceutically acceptable excipient, carrier or sustained-release matrix.